AJANTPHARM / Q3-FY24 / claim-ledger

Audit the questions that mattered.

Ajanta Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ3-FY24 · 2024-01-30Back to quarter ↗

Questions audited

Answered directly

96%

Numeric claims

Consistency

mixed

Question ledger

What was answered, and how?

Rashmi Shetty · Dolat Capital

direct

Red Sea impact on Asia and Africa sales in Q4?

No, not significantly. I think whatever guidances we have given for each of the regions we should be able to meet those guidances.

Rashmi Shetty · Dolat Capital

direct

Growth outlook for Asia and Africa in FY25-26?

Going forward also, we expect around the low-teens to mid-teens numbers for Africa and Asia.

Rashmi Shetty · Dolat Capital

direct

Outlook for institutional business next two years?

We can expect it to be a flattish kind of growth for the institution business.

Sudarshan Padmanabhan · JM Financial PMS

direct

Strategy to improve growth in cardiovascular segment?

One is new product launches. ... And second is just to gain market share by way of increasing more CRM activities... we should be able to once again record faster growth compared to the industry.

Sudarshan Padmanabhan · JM Financial PMS

direct

Will Ajanta acquire brands or divisions?

Certainly, we are always on the lookout for suitable, brand acquisition targets and also opportunities. ... Inorganic growth is most welcome for us.

Sudarshan Padmanabhan · JM Financial PMS

direct

Sustainability of 27-28% EBITDA margins and Red Sea risk?

The freight can go up by 0.5%, overall, so which can translate into around INR 30-35 crore increase cost as compared to the current year. ... we don't see as materially impacting whatever is there.

Sudarshan Padmanabhan · JM Financial PMS

direct

Chantix launch timeline and US price erosion?

The price erosion has slowed down. ... we are looking at a Q1 of the next year launch for the Chantix.

Aman Kumar Singh · Research desk

direct

Impact of anti-malarial vaccine on Ajanta's business?

Next, 3-5 years, we don't see the vaccines to be having a meaningful impact on the anti-malarial market in Africa.

Aman Kumar Singh · Research desk

direct

Why not deploy cash more meaningfully instead of dividends?

The only way we can use the cash is only for the acquisitions. ... we don't have any candidate for which we would like to keep the cash in the company.

Harsh Bhatia · Bandhan AMC

direct

Cardiac underperformance: NLEM impact or market share loss?

Major impact is because of the NLEM, price reductions that have happened. But, also, ... competitive intensity in the marketplace has increased... there is some small bit of maybe insignificant, market loss happening.

Kunal Randeria · Axis Capital

direct

R&D spend and ANDA filing plans?

Next year, we are taking the target of 8-12 ANDAs. ... There'll be a marginal increase in the R&D spend, but probably percentage-wise, it should remain around the same of the current year.

Kunal Randeria · Axis Capital

partial

Risk to margins reaching 30% in a couple of years?

U.S. price erosion is one unknown variable ... Second could be institution business ... Going forward also, we believe that in the coming years, it should inch up.